

# **Clinical Commissioning Policy: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (adults)**

NHS England Reference: 170078P



# **Clinical Commissioning Policy: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (adults)**

First published: August 2018

**Prepared by NHS England Specialised Services Clinical Reference Group for  
Specialised Respiratory**

Published by NHS England, in electronic format only.

Gateway reference: 07603

## Contents

Policy statement .....	4
Equality Statement.....	4
Plain language summary .....	4
1 Introduction .....	6
2 Definitions .....	6
3 Aims and objectives .....	7
4 Epidemiology and needs assessment.....	7
5 Evidence base.....	9
6 Criteria for commissioning.....	12
7 Patient pathway.....	13
8 Governance arrangements .....	13
9 Mechanism for funding.....	14
10 Audit requirements .....	14
11 Documents which have informed this policy .....	14
12 Date of review .....	14
References.....	15

## Policy statement

NHS England will commission levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (adults) in accordance with the criteria outlined in this document.

In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources.

This policy document outlines the arrangements for funding of this treatment for the population in England.

Our policies provide access on the basis that the prices of therapies will be at or below the prices and commercial terms submitted for consideration at the time evaluated. NHS England reserves the right to suspend or rescind policies where the supplier of an intervention is no longer willing to supply the treatment to the NHS at or below this price and to review policies where the supplier is unable or unwilling to match price reductions in alternative therapies.

## Equality Statement

Promoting equality and addressing health inequalities are at the heart of NHS England's values. Throughout the development of the policies and processes cited in this document, we have:

- given due regard to the need to eliminate discrimination, harassment and victimisation, to advance equality of opportunity, and to foster good relations between people who share a relevant protected characteristic (as cited under the Equality Act 2010) and those who do not share it; and
- given regard to the need to reduce inequalities between patients in access to, and outcomes from healthcare services and to ensure services are provided in an integrated way where this might reduce health inequalities.

## Plain language summary

### About cystic fibrosis

Cystic fibrosis (CF) is the most common, life-limiting, inherited disease in the UK. It affects about 7,700 people in England.

Cystic fibrosis is caused by a single faulty gene that controls the movement of salt in the body. In people with cystic fibrosis, the lungs become clogged with thick, sticky mucus resulting in infections and inflammation that make it hard to breathe. They also have problems digesting food as the thick mucus blocks the release of

secretions in to the gut. People with cystic fibrosis can also have other problems including diabetes, infertility and osteoporosis.

### **About current treatments**

Inhaled therapies are used to relieve tightness in airways and inflammation in the lungs, reduce the stickiness of mucus in the airways or treat serious infections in the lungs.

Inhaled antibiotics are a normal treatment for people with cystic fibrosis with chronic lung infection.

### **About the new treatment**

Inhaled levofloxacin is a new antibiotic to provide an extra option for treatment.

### **What we have decided**

NHS England has carefully reviewed the evidence to treat chronic Pseudomonas lung infection in cystic fibrosis with Levofloxacin nebulise solution. We have concluded that there is enough evidence to make the treatment available at this time.

## 1 Introduction

Cystic fibrosis (CF) is the most common autosomal recessive life-limiting genetic condition in the United Kingdom. Despite modern management the average age of death is still only 29 years. More than 90% of premature deaths are directly due to lung infections. The lungs of people with CF can become infected by bacteria (most commonly *Pseudomonas aeruginosa* (Pa)), bacterial infection is rarely eradicated once chronic infection has developed. The guideline on antibiotic treatment for CF from the Cystic Fibrosis Trust (2009) advises that people with CF and chronic pulmonary *Pseudomonas aeruginosa* infection should be recommended for regular nebulised anti-pseudomonal antibiotic treatment. At the time of publication of that guideline, colistimethate sodium and tobramycin were the only nebulised antibiotics licensed for the treatment of chronic *Pseudomonas aeruginosa* infection in people with CF. The guideline recommends that initial treatment should be with nebulised colistimethate sodium with tobramycin as a second-line agent. Subsequently a third inhaled antibiotic has become available - aztreonam lysine and NHS England has published a clinical policy on the use of all three agents which states that colistimethate sodium should be used first line, tobramycin second line, and aztreonam lysine used third line (<https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/01/a01-policy-inhld-thrpy-cf.pdf>).

This policy describes the rationale for the use of inhaled Levofloxacin in people with CF, the indications for its use and for future monitoring.

## 2 Definitions

Cystic fibrosis is a genetic condition defined by a mutation in both copies of a person's genes that code for an important protein called CF Transmembrane Conductance Regulator. People with CF typically have lung damage (bronchiectasis), chronic sinus problems, bowel problems (including malabsorption, malnutrition, diarrhoea and constipation), and fertility problems.

*Pseudomonas aeruginosa* is a bacterial species characterised as being a Gram negative bacillus. Found widely in the environment, it is also a characteristic finding in the lungs of people with CF. It is particularly virulent and associated with a significantly worse prognosis than those people with CF who do not have it chronically.

Levofloxacin inhalation solution (LIS) is an antibiotic manufactured and licensed for use in people with CF. Its antimicrobial properties are targeted against *Pseudomonas aeruginosa*.

### 3 Aims and objectives

This policy aims to describe the clinical criteria under which NHS England will routinely fund the inhaled therapy levofloxacin inhalation solution (LIS) for people with cystic fibrosis.

The objectives are to:

- a) describe which groups of people with CF may benefit from the use of LIS
- b) describe in what circumstances use of LIS should be approved
- c) describe the use of LIS in respect to other inhaled antibiotic approved for use in people with cystic fibrosis by NHS England, as laid out in the Clinical Commissioning Policy: Inhaled Therapy for Adults and Children with Cystic Fibrosis. <https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/01/a01-policy-inhld-thrpy-cf.pdf>

### 4 Epidemiology and needs assessment

CF is the most common, life-limiting, recessively inherited disease in the UK, affecting around 7,700 people in England. It affects all mucus producing cells resulting in dehydrated secretions throughout the body, particularly damaging to the lungs, the gut and the pancreas. These secretions become thick and block the airways and the flow of digestive juices in the gut. As a result, patients get recurrent and long-term infections in the lungs (which are the main cause of morbidity and mortality) and have problems with the digestion and absorption of food resulting in poor growth. Median survival for patients with CF is currently 47 years (UK CF Registry 2015). However, the median age at death is currently 28 years. Most people with CF who die each year are young adults.

CF is generally progressive over time as lung tissue becomes more damaged. With age, patients are more likely to need longer courses of medication, and longer and more frequent periods in hospital. Severely ill patients may need lung, heart or heart/lung transplants. Annual expenditure on standard care (excluding transplantation) for CF in England is around £100m.

NHS England has a formal clinical commissioning policy to fund inhaled therapies for patients which includes treatment for the commonest and most serious infection: pulmonary *Pseudomonas aeruginosa* infection (A01/P/b). Approximately 50% of people with CF are either chronically or intermittently colonised with Pa (UK National Registry Report 2015) Three antibiotics are funded, in a stepwise approach i.e. colistimethate, tobramycin and aztreonam.

90% of deaths in patients with CF are due to chronic pulmonary infection with associated lung damage and respiratory failure. Inhaled antibiotics are an essential strategy to treat these infections, and for slowing and preventing the resulting pulmonary damage. The three currently commissioned antibiotics (colistimethate,

tobramycin and aztreonam) may be or become unsuitable for some individual patients due to intolerability, microbial resistance or clinical deterioration. Therefore there is a need for new inhaled antibiotics with activity against *Pseudomonas aeruginosa*.

It is estimated that there are around 2400 people in England with CF who are aged 12 years or older and who have chronic airways colonisation with *Pseudomonas aeruginosa* (UK CF Registry).

LIS is licensed for use in people with CF who are chronically colonised with *Pseudomonas aeruginosa* age 18 years and over. Evidence is presented from trials in people with CF from age 12 years and older. However, the NICE Rapid Evidence Review and the NHS England Specialised Commissioning Policy Working Group were concerned about the use of LIS in the 12-17 age group, due to reported significant systemic absorption of LIS and the potential effects on the musculoskeletal-skeletal system when still developing. Thus, those aged less than 18 years are excluded from the scope of this clinical commissioning policy.

The following data relating to England are extracted from The UK National CF Registry by personal communication. The full 2015 registry report is publicly available at [www.cysticfibrosis.org.uk](http://www.cysticfibrosis.org.uk). In 2015 the UK National Registry reported 4450 people with CF aged 18 years and over in England. Of these there are 2191 (49%) with chronic *Pseudomonas aeruginosa*. Of these 1965/2191 (90%) were prescribed at least one inhaled antibiotic.

In order to estimate how many people with CF might be prescribed LIS, the uptake of the most recent inhaled antibiotic to be approved for use in people with CF in the UK was used as a comparator. Aztreonam lysine became available in 2009, and was approved for use within the policy laid out in the 2012 NHS England Clinical Commissioning Policy: Inhaled Therapy for Adults and Children with Cystic Fibrosis. Using data captured by the CF National Registry, the increase in use of aztreonam lysine following its approval is as follows (where N is the number of people with CF age 18 years and older attending Cystic Fibrosis Centres in England):

- 2012:  $N=89/3536=3\%$
- 2013:  $N=271/3816=7\%$
- 2014:  $N=527/4057=13\%$
- 2015:  $N=602/4450=13.5\%$

It is expected that the future use of LIS by people with CF in England will be no more than that seen for aztreonam lysine, and indeed is likely to be less. This is because the use of LIS is proposed as a fourth line agent, after tobramycin, colistimethate sodium and aztreonam lysine have been tried.

The rationale is that whilst there are no studies comparing aztreonam and levofloxacin, those comparing aztreonam and tobramycin (against which levofloxacin has been compared) showed a much more convincing benefit for aztreonam. In addition, there is significant systemic absorption of levofloxacin, and the quinolones

are a class with a wide variety of potential side effects (already recognised in the restriction of the licence to >18yr olds).

## 5 Evidence base

It can be difficult to research the use of antipseudomonal drugs in patients with CF.

- It is now common practice to rotate inhaled antibiotics by cycle which means that studies which require administration of repeated cycles of the same product are unlikely to be feasible.
- Very few participants naïve to inhaled antibiotic treatment can be enrolled to studies.
- The age at which chronic colonisation with *Pseudomonas aeruginosa* occurs has generally increased which has impacted on the number of young people who can be recruited to studies.

There are no published studies which directly compare nebulised levofloxacin and nebulised aztreonam. There are also no published studies comparing nebulised levofloxacin with another inhaled antibiotic in a population of people naïve to both antibiotics.

There are two key studies concerning the efficacy and safety of nebulised levofloxacin for the management of chronic pulmonary infections due to *Pseudomonas aeruginosa* in people with CF. Flume et al (2016) is a double blind randomised controlled trial (RCT) comparing 28 days of nebulised levofloxacin with placebo. Elborn et al (2015) is an open-label randomised non-inferiority study comparing nebulised levofloxacin with nebulised tobramycin over three cycles of treatment.

### **Flume et al (2016)**

This study was a multicentre, double-blind, placebo-controlled RCT of one cycle of treatment consisting of 28 days treatment and 28 days follow up. The study included 330 patients (55% male) aged over 12 years (mean age 29 years; 85% were aged over 18 years), with a documented diagnosis of CF, a forced expiratory volume in 1 second (FEV1) between 25% and 85% of predicted (mean 56.5%), and a chronic airways infection with *Pseudomonas aeruginosa* (defined as a respiratory secretion culture positive for *Pseudomonas aeruginosa* in the previous 12 months and a positive culture obtained at the screening visit) who had received at least three 28 day courses (or a total of 84 days) of inhaled antibiotics over the previous 12 months, with at least a 14 day course completed within the previous 29 to 84 days.

Patients were randomised 2:1 to either levofloxacin 240 mg nebulised twice daily or 0.9% saline nebulised twice daily. The treatments were blinded for appearance but not taste. Patients continued their usual respiratory care and medications during this

study. Antipseudomonal antibiotics other than the study drug were not allowed unless it was deemed necessary to treat a suspected exacerbation by the study investigator.

The primary outcome measure was time to an exacerbation of CF, defined by concurrently having changes in at least four of the 12 respiratory signs or symptoms that make up the modified Fuchs definition (Fuchs et al 1994), or any of the following: early discontinuation from the study, death or treatment with an antipseudomonal antibiotic for an event that did not meet the predefined criteria but was determined to be an exacerbation for the purposes of the primary endpoint by an independent, blinded, exacerbation adjudication committee.

Analysis was by intention to treat.

The median time to first exacerbation was 51.5 days in the levofloxacin group compared to 58.0 days in the placebo group (difference not statistically significant).

The mean change in *Pseudomonas aeruginosa* sputum density ( $\log_{10}$  (colony forming units) per gram) was -0.59 in the levofloxacin group compared to 0.04 in the placebo group ( $p < 0.05$ ).

The mean change from baseline to Day 28 in the respiratory domain of the Cystic Fibrosis Questionnaire Revised (CFQ-R) was 4.66 in the levofloxacin group compared to 4.94 in the placebo group (difference not statistically significant).

3.2% of patients in the levofloxacin group reported serious adverse events, compared to none in the placebo group. 4/219 patients in the levofloxacin group withdrew from the study, compared to 1/110 in the placebo group.

### **Elborn et al. 2015**

This study was a multicentre open-label comparator randomised trial of three cycles of treatment with each cycle consisting of 28 days treatment and 28 days follow up. Participants and study co-ordinators were aware of the treatment assignment but the site investigators and medical monitors remained blinded.

The study involved 282 patients (57% male) aged 12 years or over (mean age 28 years; 86% were over 18 years) with a documented diagnosis of CF, a FEV1 between 25% and 85% predicted (mean 54%), and a chronic airways infection with *Pseudomonas aeruginosa* who had received at least three 28 day courses (or a total of 84 days) of inhaled tobramycin over the previous 12 months, with at least a 14 day course completed within the previous 29 to 56 days. Chronic *Pseudomonas aeruginosa* infection was defined as a respiratory secretion culture positive for *Pseudomonas aeruginosa* in the previous 12 months and a positive culture obtained at the screening visit.

Participants were randomised 2:1 to either levofloxacin 240 mg nebulised twice a day or tobramycin 300 mg nebulised twice daily. Participants were able to continue

their routine respiratory care and medications during the study. Antipseudomonal antibiotics other than the study drug were not allowed unless it was deemed necessary to treat a suspected exacerbation by the study investigator.

The primary efficacy outcome was the relative change in FEV1 percentage predicted from baseline to Day 28. The study was designed to show the non-inferiority of nebulised levofloxacin to nebulised tobramycin for the primary outcome with a pre-specified non-inferiority margin of a lower 95% confidence interval greater than -4%. If non-inferiority was demonstrated then a subsequent test for superiority of levofloxacin was to be conducted.

Analysis was by intention to treat.

The percentage predicted FEV1 in the levofloxacin group was 54.8% at baseline and 56.0% at day 28. This compared to the tobramycin group where it was 52.2% at baseline and 53.3% at day 28. The mean relative change was not statistically significant i.e. levofloxacin was non-inferior to tobramycin but not superior.

Median time to first exacerbation was 131 days in the levofloxacin group compared to 90.5 days in the tobramycin group (difference not statistically significant).

Median time to administration of antipseudomonal antibiotics other than the study drug was 141 days in the levofloxacin group compared to 110 days in the tobramycin group ( $p=0.04$ ).

Median change in *Pseudomonas aeruginosa* sputum density ( $\log_{10}$  CFUs per gram) in the levofloxacin group was -0.51 from baseline to day 28, and -0.13 from baseline to day 168. In the tobramycin group the median change in sputum density was -0.87 from baseline to Day 28 and -0.25 from baseline to day 168 (difference between the two drugs not statistically significant).

22.0% of patients treated with levofloxacin and 32.2% of patients treated with tobramycin reported serious adverse events.

LIS is not licensed for use in children and young people aged less than 18 years. The manufacturers had originally submitted a license application which included children and young people from the age of 12 years and 30 kg body weight. However, due to safety concerns the manufacturer withdrew the license application for children and young people under 18 years. Further safety studies including safety studies in children and young people under 18 years are planned.

The European Public Assessment Report (EPAR) for levofloxacin reported that serum concentrations of levofloxacin from nebulised administration were on average approximately 50% of that seen with oral and intravenous routes of administration (at a dose of 500 mg daily), Therefore all of the possible adverse effects associated with oral or intravenous administration of levofloxacin (with the exception of those specific to the route of administration) are also a potential risk with the nebulised formulation. This is reflected in the summary of product characteristics which includes warnings and precautions for use associated with systemic administration of levofloxacin and

the fluoroquinolone class of antibiotics, as well as those specific for inhaled administration (such as bronchospasm).

## 6 Criteria for commissioning

Treatment with LIS will be routinely funded in the circumstances outlined below. This guidance should be read in conjunction with the NHS England Clinical Commissioning Policy: Inhaled Therapy for Adults and Children with Cystic Fibrosis. This guidance applies to adults only. LIS is effective for the treatment of chronic pulmonary *Pseudomonas aeruginosa* infection for people with CF age 18 years and older. However other therapies are available for the same indication which have greater evidence of efficacy, without evidence of significant systemic absorption and with less risk of side effects.

- Treatment with LIS should only be initiated by a specialist CF centre.
- Treatment with LIS should only be initiated in adults aged 18 years and over with evidence of chronic *Pseudomonas aeruginosa* infection - commonly accepted as at least half the samples taken in the previous twelve months culture positive for *Pseudomonas aeruginosa*.
- LIS should be considered a fourth line therapy after colistimethate sodium, tobramycin, and aztreonam lysine.
- Treatment with LIS should only be initiated after due consideration has been given to the other inhaled antibiotic options listed above. Treatment with LIS should only be initiated if the other options are either intolerable, or have failed to provide an adequate clinical response, or are deemed to be not suitable by the treating CF clinician for other valid clinical reasons.
- Reasons for deeming treatment failure with other inhaled antibiotics include: continued accelerated decline in lung function (greater than 2% per year decline in FEV1 as percent of predicted); continued excessive i.e. more than two exacerbations requiring rescue intravenous antibiotics in a year; intolerance or allergy to alternative inhaled antibiotics.
- The licensed dosing schedule of “alternating cycles of 28 days on treatment followed by 28 days off treatment” should be employed.
- This may be prescribed alone or alternating with either colistin or tobramycin depending on clinical response to those medications previously.
- In keeping with the current NHS England policy for inhaled antibiotics in CF, it is not recommended to use LIS in an alternating cycle with aztreonam lysine, nor continuously, as such combinations have not been shown to be cost effective.
- NHS England will continue to monitor published available evidence of the efficacy and cost effectiveness of inhaled antibiotics for people with CF and may choose to order a review if it is deemed that sufficient new evidence has become available.

Contraindications:

- Known allergy to levofloxacin or to other quinolone antibiotic (moxifloxacin, ciprofloxacin, ofloxacin)
- Previously suffering with tendonitis or tendon rupture associated with the use of a quinolone antibiotic
- Epilepsy
- Pregnancy

## 7 Patient pathway

This pathway is only for patients aged 18 years and over. However the NHS England Clinical Commissioning Policy for Inhaled Therapy for Adults and Children with Cystic Fibrosis (A01/P/b; 2015) remains valid. The policy states:

- All patients should be prescribed a supervised test dose of a new inhaled antibiotic in the hospital environment before commencing therapy. An inhaled or nebulised bronchodilator should be administered before the test dose if this is part of the patient's current regimen. The test dose should be supervised by a nurse, physiotherapist or lung function technician and the patient should have pre and post dose FEV1 and FVC measured. The patient should also be monitored for post-dose wheezing and bronchoconstriction.
- The test dose may be repeated at least 24 hours later if wheezing or bronchoconstriction occurs, after the administration of nebulised bronchodilator (if not administered before the first test dose). If the patient tolerates the repeated test dose, they should use nebulised bronchodilator before each subsequent dose.
- All patients should have regular review of sputum microbiology to ensure continued appropriate ongoing treatment. If *Pseudomonas aeruginosa* has not been isolated or has been replaced by a new organism (i.e. *Burkholderia cepacia*) then a change of therapy should be considered.
- All patients should have a regular assessment of lung function to ensure ongoing treatment tolerance and identification of adverse effects. If there is evidence of bronchoconstriction associated with ongoing therapy, then the inhaled antibiotic should be discontinued and an alternative tried.
- Due to the significant systemic absorption of LIS interactions with other medications should be monitored.

## 8 Governance arrangements

See NHS England Specialised Services service specification for cystic fibrosis services (A01/S/a).

## **9 Mechanism for funding**

Named inhaled therapies (as detailed in this policy) are medicines that are excluded from the national year-of-care CF tariff. They are funded by pass through payments made against invoices raised by provider Trusts.

## **10 Audit requirements**

Services will meet the minimum dataset requirements of the UK CF Registry as detailed in the cystic fibrosis service specifications.

## **11 Documents which have informed this policy**

NHS England Clinical Commissioning Policy: Inhaled Therapy for Adults and Children with Cystic Fibrosis Reference A01/P/b (2015). Available from <https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/01/a01-policy-inhld-thrpy-cf.pdf> [accessed 3rd November 2016]

Assael B et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial (2013) *Journal of Cystic Fibrosis*. 12(2), 130-40.

Doring G, Flume P, Heijerman H, Elborn JS. Treatment of lung infection in patients with cystic fibrosis: current and future strategies (2012). *Journal of Cystic Fibrosis*. 11(6), 461-79.

## **12 Date of review**

This document will be reviewed when information is received which indicates that the policy requires revision.

## References

- Assael B et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial (2013) *Journal of Cystic Fibrosis*. 12(2), 130-40.
- Doring G, Flume P, Heijerman H, Elborn JS. Treatment of lung infection in patients with cystic fibrosis: current and future strategies (2012). *Journal of Cystic Fibrosis*. 11(6), 461-79.
- Elborn JS, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, et al. (2008) A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT- 1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. *Journal of Cystic Fibrosis*.14(4), 507-14
- European Medicines Agency. Assessment report: levofloxacin Quinsair EMEA/H/C/002789/0000. 18 December 2014. Available at [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Public\\_assessment\\_report/human/002789/WC500187847.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002789/WC500187847.pdf) [accessed 3rd November 2016]
- Flume PA, et al (2016) A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution in stable Cystic Fibrosis patients, *J Cyst Fibros*. 15 (4), 495-502, Available at <http://dx.doi.org/10.1016/j.jcf.2015.12.004> [accessed 3rd November 2016]
- Fuchs HJ et al, for the Pulmozyme Study Group\* (1994) *N Engl J Med*; 331:637-642
- NHS England Clinical Commissioning Policy: Inhaled Therapy for Adults and Children with Cystic Fibrosis Reference A01/P/b (2015). Available from <https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/01/a01-policy-inhld-thrpy-cf.pdf> [accessed 3rd November 2016]
- Raptor Pharmaceuticals Europe B.V. Summary of Product Characteristics. Levofloxacin (Quinsair) nebuliser solution. Available at [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/002789/WC500187845.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002789/WC500187845.pdf) [accessed 3rd November 2016]
- UK Cystic Fibrosis 2015 Annual Data Report (2015) Available at [https://www.cysticfibrosis.org.uk/~/\\_media/documents/the-work-we-do/uk-cf-registry/full-registry-report-2015.ashx?la=en](https://www.cysticfibrosis.org.uk/~/_media/documents/the-work-we-do/uk-cf-registry/full-registry-report-2015.ashx?la=en) [accessed 3<sup>rd</sup> November 2016]